An announcement from Portage Biotech Inc ( (PRTG) ) is now available.
On March 27, 2025, Portage Biotech Inc. announced promising preclinical results for their drug PORT-7, a selective Adenosine A2B receptor inhibitor, in treating mesothelioma. The data, presented at the 2025 European Lung Cancer Congress, showed significant tumor growth inhibition when PORT-7 was used alone or in combination with an anti-PD1 antibody in a murine model. This development supports the initiation of a first-in-human trial for PORT-7. Additionally, Portage is advancing the dose escalation of PORT-6, with plans to combine PORT-6 and PORT-7 for a comprehensive immunotherapy approach in the ADPORT-601 trial, aiming to neutralize adenosine-mediated immune suppression and enhance anti-tumor responses.
More about Portage Biotech Inc
Portage Biotech Inc. is a clinical-stage immuno-oncology company focused on developing a pipeline of novel biologics to enhance the immune system’s ability to combat cancer.
YTD Price Performance: -6.97%
Average Trading Volume: 63,570
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.09M
Learn more about PRTG stock on TipRanks’ Stock Analysis page.